Structural elucidation of major degradation products of milbemycin oxime drug substance using LC-MS and NMR
Milbemycin oxime (MO) drug substance is a 16-membered macrocyclic lactone that exhibits a broad spectrum of biological activity and high potency towards parasites. In this study, a comprehensive forced degradation study was carried out on MO drug substance to identify and characterize its major degr...
Gespeichert in:
Veröffentlicht in: | Journal of pharmaceutical and biomedical analysis 2022-08, Vol.217, p.114862-114862, Article 114862 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Milbemycin oxime (MO) drug substance is a 16-membered macrocyclic lactone that exhibits a broad spectrum of biological activity and high potency towards parasites. In this study, a comprehensive forced degradation study was carried out on MO drug substance to identify and characterize its major degradation products (DPs). MO drug substance was subjected to acid, base, oxidation (H2O2), heat (solid and solution state), and photolytic (solid and solution state) stress degradation as per the ICH guidelines. Chromatographic separation of the drug substance (MO A3 and MO A4) and its DPs was achieved using a gradient elution on a HALO C18 column (100 × 4.6 mm, 2.7 µm). Mobile phase A consisted of water/acetonitrile (60/40, v/v) and mobile phase B consisted of ethanol/isopropanol (50/50, v/v). A total of twelve major DPs were observed for MO drug substance under various stress conditions. These DPs were further identified and characterized using liquid chromatography-high resolution mass spectrometry and comparison of their fragmentation profile with MO A4 and MO A3 using tandem mass spectrometry. Of these, H2O2 induced oxidative degradation product (3,4-dihydroperoxide MO A4) was isolated using semi-preparative HPLC and characterized by comparison of its nuclear magnetic resonance spectroscopy data with MO A4. The proposed structures of the DPs have been rationalized by appropriate degradation pathways for MO A4 and MO A3.
•Forced degradation studies of milbemycin oxime drug substance were conducted as prescribed in ICH Q1A (R2) guidelines.•Twelve degradation products were determined using a reversed-phase HPLC method.•Identification and characterization of the degradation products were performed by high-resolution mass spectrometry.•1D and 2D NMR studies were conducted for the confirmation of 3,4-dihyroperoxide MO A4.•The mechanism of degradation pathways of milbemycin oxime was postulated. |
---|---|
ISSN: | 0731-7085 1873-264X |
DOI: | 10.1016/j.jpba.2022.114862 |